Metraipolis › archive › dc_fe8ff1437005
Bridging the gap in OA therapeutics: Bioengineered strategies to target osteoclast-chondrocyte crosstalk — Europe PMC PMID:42272963
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42272963
- DOI
- 10.1002/btm2.70107
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T22:06:28.074Z
- SHA-256 of the archived text
041423c37d0fe2d5c5208a8809e75f3065359cb7fbae6d9b355f2067d932791f- Stable URL of this page
https://metraipolis.com/documento/dc_fe8ff1437005
How to cite
Bridging the gap in OA therapeutics: Bioengineered strategies to target osteoclast-chondrocyte crosstalk — Europe PMC PMID:42272963 — Europe PMC (en), https://europepmc.org/article/MED/42272963 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fe8ff1437005 (Metraipolis archive dc_fe8ff1437005, sha256 041423c37d0fe2d5c5208a8809e75f3065359cb7fbae6d9b355f2067d932791f)
BibTeX
@misc{dcfe8ff1437005,
title = {Bridging the gap in OA therapeutics: Bioengineered strategies to target osteoclast-chondrocyte crosstalk — Europe PMC PMID:42272963},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42272963},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fe8ff1437005; sha256 041423c37d0fe2d5c5208a8809e75f3065359cb7fbae6d9b355f2067d932791f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42272963. Agents can read the archived copy with the MCP tool read_document.